TNF and juvenile idiopathic arthritis: There are four types of biologics that are commonly used in JIA, namely tumor necrosis factor-α (TNF) inhibitors (infliximab, adalimumab, etanercept), B-cell inhibitors (rituximab (anti-CD-20)), interleukin inhibitors (anakinra, canakinumab, secukinumab, tocilizumab) and selective co-stimulation modulators (abatacept) [2,3].